Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs

Arzneimittelforschung. 1998 Jan;48(1):55-7.

Abstract

The effects of loxiglumide (CAS 107097-80-3, CR 1505), a novel cholecystokinin-A(CCK-A) receptor antagonist, on pancreatic exocrine secretion stimulated by meal were examined in conscious dogs with chronic pancreatic fistula. Pancreatic exocrine secretion was stimulated by intraduodenal infusion of a liquid test meal and postprandial plasma CCK levels were apparently elevated. Loxiglumide inhibited the meal-stimulated outputs of pancreatic protein, amylase and bicarbonate at an intravenous dose of 10 mg/kg/h (p < 0.05). However, loxiglumide did not show apparent inhibition of pancreatic juice volume and trypsin output. These results show that the selective CCK-A antagonist loxiglumide may inhibit the increase of pancreatic exocrine secretion based on selective blockade of receptor binding of CCK endogenously induced by meal in dogs.

MeSH terms

  • Amylases / metabolism
  • Animals
  • Bicarbonates / metabolism
  • Dogs
  • Female
  • Food-Drug Interactions*
  • Hormone Antagonists / blood
  • Hormone Antagonists / pharmacology*
  • Male
  • Pancreas / drug effects
  • Pancreas / enzymology
  • Pancreas / metabolism*
  • Pancreatic Juice / drug effects
  • Pancreatic Juice / metabolism
  • Proglumide / analogs & derivatives*
  • Proglumide / blood
  • Proglumide / pharmacology
  • Receptors, Cholecystokinin / antagonists & inhibitors*
  • Trypsin / metabolism

Substances

  • Bicarbonates
  • Hormone Antagonists
  • Receptors, Cholecystokinin
  • loxiglumide
  • Amylases
  • Trypsin
  • Proglumide